Merck
HomeWebinarsImmune Responses Associated with Losartan-TKI Combination Immunotherapy in Dogs with Metastatic Osteosarcoma

Immune Responses Associated with Losartan-TKI Combination Immunotherapy in Dogs with Metastatic Osteosarcoma

Webinar

In this webinar, Dr. Regan will present data regarding a novel immunotherapy in dogs with spontaneous metastatic osteosarcoma. This work led to clinical trials in pediatric and young adult humans with osteosarcoma.

For Research Use Only. Not For Use In Diagnostic Procedures.

Speakers

Dan Regan, DVM, PhD, DACVP

Colorado State Veterinary School

Assistant Professor

Dr. Regan is an Assistant Professor at Colorado State Veterinary School. The focus of his research is to increase our understanding of the interplay between the immune system and (non-immune) tumor stroma, and how these compartments of the tumor microenvironment promote metastasis as well as respond to and mediate extrinsic mechanisms of resistance to anti-cancer therapy. To investigate this area of cancer biology, his laboratory utilizes a combination of in vitro 3-dimensional tumor co-culture models and animal models, focusing on breast and bone cancer (osteosarcoma).